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Abstract
Background: The complement system is thought to be involved in the pathogenesis of numerous
neurological diseases. We previously reported that pre-treatment of murine cortico-hippocampal
neuronal cultures with the complement derived anaphylatoxin C5a, protects against glutamate
mediated apoptosis. Our present study with C5a receptor knock out (C5aRKO) mice
corroborates that the deficiency of C5a renders C5aRKO mouse more susceptible to apoptotic
injury in vivo. In this study we explored potential upstream mechanisms involved in C5a mediated
neuroprotection in vivo and in vitro.
Methods: Based on evidence suggesting that reduced expression of glutamate receptor subunit 2
(GluR2) may influence apoptosis in neurons, we studied the effect of human recombinant C5a on
GluR2 expression in response to glutamate neurotoxicity. Glutamate analogs were injected into
C5aRKO mice or used to treat in vitro neuronal culture and GluR2 expression were assessed in
respect with cell death.
Results: In C5aRKO mice we found that the neurons are more susceptible to excitotoxicity
resulting in apoptotic injury in the absence of the C5a receptor compared to WT control mice.
Our results suggest that C5a protects against apoptotic pathways in neurons in vitro and in vivo
through regulation of GluR2 receptor expression.
Conclusion: Complement C5a neuroprotects through regulation of GluR2 receptor subunit.
Background
The complement system is an essential effector of the
humoral and cellular immunity involved in cytolysis and
immune inflammatory responses. There is now compel-
ling evidence that complement activation in the brain is a
double-edged sword in that it can exert beneficial or det-
rimental effects depending on the pathophysiological
context [1]. Complement has been implicated in diverse
human neurodegenerative disorders such as Alzheimer's,
Huntington's and Pick's disease [2,3]
The complement system composed of more than 30 pro-
teins is not only activated by antigen-antibody complexes
but also by other molecules found in the brain, e.g. mye-
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lin and neurofilaments [4,5]. Activation of the comple-
ment cascade results in the release of several
anaphylatoxins, notable being C3a and C5a, leading to
inflammation. C3a and C5a exert their functions by bind-
ing to specific receptors, C3aR and C5aR respectively [5].
Functional roles for C3a and C5a have been described
during development of cerebellum [6], tissue regenera-
tion [7] and neuronal death [8]. C3a exerts a neuroprotec-
tive effect against excitotoxicity-induced death of neurons
that are cultured with astrocytes [9]. C5a mediates apop-
tosis in neuroblastoma cells [8], whereas, it is a potent
inhibitor of apoptotic cell death in cultured granule neu-
rons [6].
Neuronal excitation involving the excitatory glutamate
receptors is recognized as an important underlying mech-
anism in neurodegenerative disorders. Excitation result-
ing from stimulation of the ionotropic glutamate
receptors is known to cause neuronal apoptosis. Kainic
acid (KA) is an agonist for a subtype of ionotropic gluta-
mate receptor, and administration of KA has been shown
to increase production of reactive oxygen species, mito-
chondrial dysfunction, and apoptosis in neurons in brain
[10]. We had earlier reported that the complement com-
ponent C5 neuroprotects against excitotoxicity; further we
showed that mice genetically deficient of complement
component C5 revealed a higher susceptibility to KA neu-
rodegeneration [11,12] suggesting that in addition to
their pro-inflammatory mechanisms, specific comple-
ment components may also mediate neuroprotection.
This hypothesis was further supported by evidence show-
ing that C5a may neuroprotect against glutamate medi-
ated apoptosis through the regulation of mitogen
activated protein kinase (MAPK) signal transduction path-
ways [13,14] or by inhibition of caspase-3 activity [15].
Based on the evidence that neuronal death in response to
excitotoxic insult involves the regulation of GluR2 recep-
tor expression [16] and that GluR2 receptor expression is
reduced coincidental to increase in expression of apop-
totic markers like caspase 3 in Alzheimer's brain [17] we
decided to explore the role of GluR2 receptors in C5a
mediated protection in vivo and in vitro. In the present
study using C5a receptor knockout (C5aRKO) mice we
found that neurons were more susceptible to excitotoxic-
ity resulting in apoptotic injury in the absence of the C5a
receptor. Our study suggests that C5a may protect against
neurodegenerative excitotoxicity and apoptosis in neuro-
nal cells through the regulation of GluR2 receptor expres-
sion in vitro and in vivo.
Methods
Primary neuron cultures
Primary cortico-hippocampal cultures of mouse embry-
onic neurons (gestational day 14–16) were prepared as
previously described [15]. Briefly, neurons were seeded at
2 × 105 cells/well in poly-D-lysine (Sigma) coated 96-well
plates or at 106 cells/well in poly-D-lysine coated 6-well
plates and cultured in serum-free chemically defined
medium Neurobasal/B27 (2%) supplement and 1% Pen-
icillin-Streptomycin (Gibco-BRL). The absence of astro-
cytes (<1–2%) was confirmed by the lack of glial fibrillary
acidic protein (GFAP) immunostaining verified in parallel
studies (data not shown). Northern blot hybridization of
total RNA confirmed C5a receptor (C5aR) expression in
these primary cortico-hippocampal neurons as previously
described [15].
Human recombinant (hr) C5a and glutamate toxicity
The hrC5a (Sigma) was solubilized in phosphate buffered
saline (PBS) and stored at -20°C in disposable 50 µM
aliquots; purity was verified by PAGE-Coomassie blue
(BRL) as previously described [15]. Chemokinetic
potency of hrC5a (EC50: 1.2 × 10-10 M in human neu-
trophil) was assessed for biological activity (H. Osaka and
G.M. Pasinetti, unpublished observations). In our studies,
l-glutamate (Sigma) was dissolved in PBS (pH 7.4) and
stored at 4°C in 500 mM aliquots, the C5aR antagonist
C177 (gift of Dr. Martin Springer, Merck, NJ; 18), was
stored in disposable 1 mM aliquots in PBS at -20°C and
the MAPK pathway inhibitor PD98059 (Calbiochem) was
solubilized in DMSO and stored at -20°C in 10 mM aliq-
uots. Disposable aliquots of DMSO were also stored at -
20°C to mimic freeze thaw conditions in vehicle treated
cultures. Cultures were treated with glutamate, hrC5a,
C177, PD98059 or vehicle (0.001% PBS or 0.01% DMSO,
final concentration), as indicated. Glutamate exposure
was performed in 7 days old cultures by adding 50 µM
glutamate from concentrated stocks into the existing cul-
ture media for 24 hr until neuron cultures were collected
for viability assays. All cultures and reagents were demon-
strated to be free of endotoxin (<10 pg/ml) by Limulus
lysate assay (Sigma).
Kainic Acid (KA) mediated lesions
All procedures involving animals met the guidelines
described in the NIH Guide for the Care and Use of Labora-
tory Animals and had been approved by the Animal Facility
of the Mount Sinai School of Medicine. Adult male C57B6
mice (25–36 g) (n = 4) were injected intraventricularly
with KA (Sigma) to induce hippocampal lesions as previ-
ously described [11]. Mice were anesthetized using Aver-
tin (tribromoethanol, 125 mg/kg body weight). KA (80
ng/0.5 µl volume) or vehicle (0.5 µl PBS) was injected
unilaterally into wild type (WT) (control mice) (n = 4)
and C5aRKO mice (n = 4) in the lateral ventricle using a 5Journal of Neuroinflammation 2008, 5:5 http://www.jneuroinflammation.com/content/5/1/5
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µl Hamilton syringe attached to stereotaxic apparatus.
Mice were sacrificed 72 hr after injection and brains were
quickly removed, rinsed in cold PBS and immersed in
methylbutane at -25°C for 3 min. 10 micron slices from
the frozen brains were mounted on polylysine-coated
slides and stored at -70°C.
Lactic acid dehydrogenase (LDH) Assay
Glutamate neurotoxicity was assessed by measuring the
lactate dehydrogenase (LDH) released in culture media 24
hr after glutamate treatment using the Cytotox 96 non-
radioactive cytotoxicity assay kit (Promega) (n = 6, exper-
iment repeated three times). Results were quantitated by
measuring the wavelength absorbance at 490 nm and
were normalized to total LDH in the cells. LDH release
was also measured in vehicle treated cultures to control
for the effects of DMSO or PBS on cell viability. Data are
expressed as percentage of control.
Hematoxylin and eosin (H&E) staining
Assessment of morphological features of apoptotic dam-
age was done by counting neurons with evident pyknotic
condensed nuclei surrounded by cytoplasmic eosi-
nophilia using H&E staining as previously described (12).
Primary neuronal cultures plated on chambered slides
were fixed in 100% methanol for 10 min., and air-dried.
Damaged neurons were quantified in vitro from 8–10 ran-
domly selected fields. 10 µm slices from KA and vehicle
injected brains of C5aRKO and WT mice were mounted
on polylysine-coated slides and damaged neurons were
quantified in vivo from the different anatomical regions of
the hippocampal formation in each brain slice.
In situ labeling of fragmented DNA (TUNEL assay)
Apoptotic neurons were identified using the terminal
deoxynucleotidyl transferase nick end labeling (TUNEL)
method of detecting fragmented DNA using the ApopTag
kit (Intergen) (n = 4). Briefly, primary cortico-hippocam-
pal cultures on chamber slides were fixed in 100% meth-
anol (15 min) and air-dried following appropriate
glutamate and/or hrC5a treatment. The fixed slide cul-
tures were then re-hydrated in PBS and incubated in 0.3%
H2O2 for 5 min. at room temperature. Next, the slides
were incubated with TdT enzyme in a humidified cham-
ber at 37°C for 1 hr, followed by 30 min. incubation with
anti-Digoxigenin conjugate. TUNEL positive cells were
visualized using the chromogen 3-3-Diaminobenzidine
(DAB) using the ABC substrate kit (Vector) and mounted
for microscopy. Results were quantitated from 8–10 ran-
domly selected fields per well (n = 4 wells).
Immunocytochemical (ICC) detection of GluR2
For ICC, slides were re-hydrated in phosphate buffered
saline (PBS) and incubated in 0.3% H2O2 for 30 min to
block endogenous peroxidase activity. The slides were
subsequently incubated with a monoclonal antibody
against GluR2 (1:100) (gift of Dr. JH Morrison, Mount
Sinai School of Medicine, NY) [19] overnight at 4°C, fol-
lowed by incubation with secondary antibody (goat anti-
mouse HRP; Pharmingen, CA) (1:200) for 60 min. at
room temperature. Neurons positive for GluR2 were visu-
alized with DAB using the ABC kit (Vector) (n = 6 slides
per group). The slides were then dehydrated in ascending
ethanol series, cleared in xylene and mounted with Per-
mount (Sigma) for microscopy. The immunostaining
densities were digitized with a high-resolution charge-
coupled-device camera (Sony, Tokyo, Japan) and semi-
quantified using Bioquant computer-assisted densitome-
try (Biometrics, Nashville, TN). Camera aperture and
focus were adjusted to provide an optimal image. The
overall illumination was also adjusted so that the distribu-
tion of relative gray values, ie., number of pixels in the
image as a function of gray value (0–255), fell within the
limits of the system, typically within 30 to 220 gray value
units, avoiding a floor or ceiling effect. Once established,
the setting remained constant for all the images acquired
for all the ICC experiments. Therefore, when all the
parameters were fixed, only tissue staining intensities
influenced the measured gray value. GluR2 immunoreac-
tive neurons were quantitated from 8–10 randomly
selected fields per well (n = 6 wells) and results were
expressed as a percent of control.
Statistical analyses
Difference between groups was assessed by t-test. One way
ANOVA was used to compare three or more treatments.
Bonferroni's multiple comparison tests was used to detect
differences between treatments. For all statistical analyses,
the null hypothesis was rejected at p < 0.05.
Results
C5aRKO mice are more susceptible to KA excitotoxicity 
and apoptosis than WT littermates
The excitatory neurotransmitter glutamate is known to
play an important role in the induction of excitotoxic neu-
rodegeneration through activation of its receptors. Kainic
acid (KA) is a potent glutamate receptor agonist with
selectivity towards non-NMDA type glutamate receptors.
Both apoptotic and necrotic death of neurons are associ-
ated with KA-induced excitotoxicity, suggesting the exist-
ence of multiple death pathways induced by glutamate
receptor neurotoxicity. Histology performed with hema-
toxylin/eosin on brain slices from C5aRKO and WT
C57B6 mice suggested that C5aRKO mice are more sus-
ceptible to KA induced neurodegeneration than age and
gender matched WT mice. Furthermore, KA lesions in
C5aRKO mice resulted in greater number of TUNEL posi-
tive neurons than in KA injected WT littermates (Fig. 1)
(ANOVA: Hematoxylin/eosin WT and C5aRKO – KA
induced: p < 0.01; TUNEL WT and C5aRKO – KA induced:Journal of Neuroinflammation 2008, 5:5 http://www.jneuroinflammation.com/content/5/1/5
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p < 0.006). This result suggests that C5aR exerts a neuro-
protective role against KA-induced neurotoxicity.
C5aRKO mice show decreased GluR2 expression in vivo in 
response to KA compared to WT littermates
Non-NMDA receptor ion channels that can be gated by
KA are formed by the glutamate receptor subunits GluR1-
GluR4. GluR2 is downregulated in neurons following a
wide range of neurological insults [33] and our subse-
quent study focused on the role of KA on GluR2 in
C5aRKO and its WT control. When KA was administered
intraventricularly in C5aRKO and wild type mice, we
found that the immunostaining of GluR2 receptor protein
expression was decreased in C5aRKO mice in response to
KA lesions as assessed by immunocytochemical analysis
(Fig. 2). Quantitation of GluR2 immunoreactivity after
treatment with KA showed a significant decrease in
expression of GluR2 in the C5aRKO mice compared to the
vehicle treated littermates (t-test: C5aRKO vehicle vs KA
induced: p < 0.05). The results suggest that C5aR plays a
neuroprotective role by upregulating GluR2 against KA-
induced neurotoxicity possibly by making the cells imper-
meable to Ca2+ influx.
Glutamate induces a receptor specific decrease in 
neuronal GluR2 expression in vitro
Previous experiments performed to characterize gluta-
mate excitotoxicity in primary cortico-hippocampal neu-
ronal cultures showed that concentrations of glutamate
ranging from 25–100 µM cause neuronal toxicity after
12–24 hr in approximately 30–75% cells in in vitro cell
culture experiments [15]. Subsequent experiments were
performed using a dose of 50 µM glutamate for 24 hr,
which achieved a significant amount of neuronal death
within the linear range of increasing glutamate toxicity
assessed by LDH assay in our culture. Moreover, treatment
of neurons with the non-competitive NMDA receptor
antagonist MK801 (10 µM) blocked glutamate toxicity
(not shown). WT primary cultures treated with glutamate
and hrC5a (100 nM) which is able to neuroprotect signif-
icantly against glutamate neurotoxicity in WT cultures did
not show significant decrease in GluR2, whereas, primary
cultures from C5aR KO mice co-treated with glutamate
and hrC5a showed significant decrease in the expression
of GluR2 (Fig. 3) (ANOVA: WT Control vs Glutamate p <
0.01; WT Control vs Glutamate+hrC5a p  < 0.0001;
C5aRKO Control vs Glutamate p < 0.006; C5aRKO Con-
trol vs Glutamate+hrC5a p < 0.006). The result suggests
that addition of hrC5a to C5aRKO mice neurons do not
decrease glutamate toxicity due to the absence of specific
C5a receptors.
C5a protection against glutamate mediated GluR2 
depletion in vitro is specific for both C5a and glutamate 
receptors
Previous studies had determined that an optimal dose of
100 nM hrC5a was required to achieve a maximal neuro-
protection when pretreated 24 hr before glutamate expo-
sure in primary murine cortico-hippocampal neurons
[14,15]. In our final experiment (repeated thrice)
designed to determine the specificity of both C5aR and
glutamate receptor we treated WT neurons with the antag-
C5aRKO mice are more susceptible to KA excitotoxicity  and apoptosis than wild type littermates Figure 1
C5aRKO mice are more susceptible to KA excitotox-
icity and apoptosis than wild type littermates. KA or 
vehicle (Veh) was administered intraventricularly in C5aRKO 
mice and age matched wild type litermates (WT) (n = 4). A. 
KA treatment in C5aRKO mice resulted in greater number 
of TUNEL positive neurons than in KA injected WT litterma-
tes (100×). The arrow points to the region in the inset show-
ing the apoptotic neurons. B. Both Hematoxylin and eosin 
(H&E) staining as well as Apoptag (TUNEL) staining methods 
of assessing apoptosis showed that there were a significantly 
greater number of apoptotic neurons in C5aRKO mice 
treated with KA than in WT mice treated with KA in the 
CA3 hippocampal region. Significance in the number of neu-
rons was assessed using one way ANOVA with Bonferroni's 
multiple testing correction. All results are expressed as mean 
± SD. Hematoxylin/eosin WT and C5aRKO – KA induced: 
*p < 0.01; TUNEL WT and C5aRKO – KA induced: *p < 
0.006. SO = stratum oriens; SR = stratum radiatum.
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onists of C5a. C5a alone enhanced the expression of
GluR2 and the C5a antagonist C177 per se had no effect
on GluR2 expression. Glutamate alone had a negative
effect on GluR2, whereas hrC5a in the presence of gluta-
mate had a positive effect, to the extent that there was an
increase in expression of GluR2. However, the hrC5a
mediated protection of GluR2 (Fig. 4) in the presence of
glutamate in primary neuronal cultures from WT mice
was absent when co-treated with C177 (ANOVA: WT Con-
trol vs Glutamate p  < 0.0001; WT Control vs Gluta-
mate+C5a p < 0.01; WT Glutamate vs Glutamate+C5a p <
0.05; Control vs Glutamate+C177+C5a p < 0.03).
Discussion
Complement has long been hypothesized to play a role in
neuroinflammation and C5a has been postulated to have
several different roles in central nervous system disease
[20]. Though it has been suggested that C5a-C5aR interac-
tion may lead to increased neuronal cell death in Alzhe-
imer's disease [8] our group has demonstrated a novel
protective role for C5a in inflammation models [14,15].
Reiman et al. [21] developed a transgenic mouse that pro-
duces C5a exclusively in the brain using the astrocyte-spe-
cific, murine glial fibrillary acidic protein (GFAP)
promoter. C5a/GFAP mice develop normally and do not
demonstrate any signs of spontaneous inflammation or
The hippocampus of C5aRKO mice show decreased GluR2  expression in vivo in response to KA when compared to WT  littermates Figure 2
The hippocampus of C5aRKO mice show decreased 
GluR2 expression in vivo in response to KA when 
compared to WT littermates. KA or vehicle (Veh) was 
administered intraventricularly in C5aRKO mice and age 
matched wild type litermates (WT) (n = 4). Frozen hippoc-
ampal brain sections from these mice were then probed 
immunocytochemically for GluR2 expression using GluR2 
antibody. GluR2 immunoreactivity was quantitated from 8–
10 randomly selected fields and results were expressed as a 
percent of vehicle treated WT controls. KA significantly 
decreased the expression of GluR2 immunoreactivity in the 
mossy fiber region of C5aRKO mice (Fig. A, B). The arrow 
points towards the region in the inset which shows the 
GluR2 immunoreactivity in the mossy fibers of the CA3 
region. Hippocampal GluR2 immunoreactivity was reduced in 
C5aRKO mice treated with KA compared to C5aRKO mice 
treated with vehicle. All results are expressed as mean ± SD. 
Difference between groups was assessed by t-test, *p < 0.05. 
SO = stratum oriens; SR = stratum radiatum; SLM = stratum 
lacunosum moleculare.
A
0
50
100
150
Vehicle Kainic Acid
WT
C5aRKO
WT
C5aRKO
G
l
u
R
2
 
I
C
C
i
n
 
v
i
v
o
(
%
 
o
f
 
V
e
h
i
c
l
e
 
T
r
e
a
t
e
d
L
i
t
t
e
r
m
a
t
e
s
)
B
*
hrC5a protected against glutamate mediated decrease in  GluR2 receptor expression in vitro Figure 3
hrC5a protected against glutamate mediated 
decrease in GluR2 receptor expression in vitro. In pri-
mary murine neuronal cultures, 50 µM glutamate for 24 hr 
significantly decreased GluR2 expression as assessed by 
GluR2 immunostaining in primary cultures from both WT 
and C5aRKO mice (n = 4). However, while WT primary cul-
tures treated with glutamate and hrC5a (100 nM) which is 
able to neuroprotect significantly against glutamate neuro-
toxicity in WT cultures did not show significant decrease in 
GluR2, primary cultures from C5aR KO mice co-treated 
with glutamate and hrC5a showed significant decrease in the 
expression of GluR2. Results were expressed as a percent of 
controls and significance was assessed using one way 
ANOVA with Bonferroni's multiple testing correction. All 
results are expressed as mean ± SD. WT Control vs Gluta-
mate: p < 0.01; WT Control vs Glutamate+hrC5a: **p < 
0.0001; C5aRKO Control vs Glutamate: *p < 0.006; 
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neurodegeneration with age. C5a also plays an important
protective role in allergic lung disease by suppressing
inflammatory responses and Th2 effector functions as
observed in an experimental model of asthma [22]. The
C5aRKO mice also develop normally and do not demon-
strate any signs of inflammation or neurodegeneration. In
this study we observed that C5aRKO mice are more sus-
ceptible to apoptosis induced by KA (an analog of gluta-
mate) stimulation compared to the WT littermates.
Neuronal injury mediated by overstimulation of receptors
for the major excitatory transmitter, glutamate (Glu), has
been implicated in a variety of neurodegenerative condi-
tions [23]. Exposure to neurotoxic concentrations of Glu
leads to necrosis via the NMDA receptors [24], while over-
stimulation of the non-NMDA receptors, KA and AMPA,
commonly produces a pattern of cell death characteristic
of apoptosis [25,26]. Activation of the NMDA receptor
stimulates JNK and p38 MAP kinases in cultured cerebel-
lar granule cells (CGCs) [27], and in hippocampal neu-
rons AMPA and KA receptors stimulate ERKs, JNK and p38
kinases [14]. KA and/or AMPA receptor stimulation
results in the marked activation of the ERK kinases in oli-
godendrocytes [28] and striatal slices [29]. There is also
evidence that C5a inhibits the spontaneous apoptosis of
neutrophils, extending their lifespan after recruitment to
sites of inflammation [30]. Other inflammatory media-
tors including perforin may facilitate this protective func-
tion of C5a [31]. We had earlier shown that C5a may
protect against glutamate-induced apoptosis in neurons
through MAPK-mediated regulation of caspase cascades
[14]. In this study we found that C5a may protect against
apoptotic pathways in neurons in vitro and in vivo in part
through regulation of GluR2 receptor expression in the
brain.
The relative presence of the GluR2 subunit determines the
functional properties of AMPA receptors, the mediators of
fast excitatory neurotransmission, play a crucial role in
synaptogenesis and formation of neuronal circuitry, as
well as in synaptic plasticity. Studies show the levels of
GluR2 mRNA and protein in CA3 and/or CA1 are down-
regulated after KA-induced seizures [16,32], indicating
that KA-induced reduction of GluR2 is related to GluR2
gene transcription. The mechanism of GluR2 downregula-
tion during KA exposure is still not established. Jia et al.
[33] reported that suppression of GluR2 gene promoter
activity is associated with KA induced downregulation of
GluR2 subunit levels in primary cultured cortical neurons.
In our studies we observed that when KA was adminis-
tered in C5aRKO, there was a reduction of GluR2 receptor
protein expression. We hypothesize that during KA
induced sensitization in the absence of C5aR, GluR2 is
downregulated leading to apoptosis. Animal models of
global ischemia and induction of status epilepticus have
demonstrated such a downregulation of GluR2 mRNA
and protein expression in the CA1 and CA3 regions of rat
hippocampus [34,35].
It is widely known that C5a functions by binding to its
specific receptor-C5aR. Our results show that exogenous
addition of hrC5a alone increases GluR2 protein expres-
sion in WT neurons, whereas there was no increase in
GluR2 protein levels in C5aRKO mouse neuron. Gluta-
mate alone was toxic for both WT and C5aRKO mouse
neuron, but the level of toxicity was lower in WT mouse
neuron in the presence of hrC5a since it could access spe-
cific C5a receptors. To prove that C5a protection against
glutamate mediated GluR2 depletion was specific for both
C5a and glutamate receptors we used the C5a antagonist-
C177. Our results show that the complement C5a neuro-
protects through regulation of GluR2, in addition to
mitogen activated protein kinase (MAPK) signal transduc-
tion pathways [13,14], and inhibition of caspase-3 activ-
ity [15].
C5a mediated protection against glutamate mediated GluR2  depletion in vitro is specific for both C5a and glutamate  receptors Figure 4
C5a mediated protection against glutamate medi-
ated GluR2 depletion in vitro is specific for both C5a 
and glutamate receptors. The hrC5a mediated protec-
tion of GluR2 in the presence of 50 µM glutamate for 24 hrs 
in primary neuronal cultures from WT mice was absent 
when co-treated with C177. All results are expressed as 
mean ± SD. WT Control vs Glutamate: **p < 0.0001; WT 
Control vs Glutamate+C5a: *p < 0.01; WT Glutamate vs 
Glutamate+C5a: *p < 0.05; Control vs Gluta-
mate+C177+C5a: *p < 0.03. The western blot shows the 
GluR2 expression in the same experiment.
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Conclusion
In conclusion we found that the complement C5a protects
against apoptotic pathways in neurons in vitro and in vivo
through regulation of GluR2 receptor subunit.
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C5a Receptor Knock Out.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Acknowledgements
Supported by NIA grants AG13799, AG14239 and AG14766 to GMP.
References
1. van Beek J, Elward K, Gasque P: Activation of complement in the
central nervous system: roles in neurodegeneration and neu-
roprotection.  Ann NY Acad Sci 2003, 992:56-71.
2. Morgan BP, Gasque P, Singharo S, Piddlesden SJ: The role of com-
plement in disorders of the nervous system.  Immunopharmacol-
ogy 1997, 38:43-50.
3. Mukherjee P, Pasinetti GM: The role of complement anaphyla-
toxin C5a in neurodegeneration: implications in Alzheimer's
disease.  J Neuroimmunol 2000, 105:124-130.
4. Pasinetti GM: Inflammatory mechanisms in neurodegenera-
tion and Alzheimer's disease: the role of the complement
system.  Neurobiol Aging 1996, 17:707-716.
5. Gasque P, Neal JW, Singhrao SK, McGreal EP, Dean YD, Van BJ, Mor-
gan BP: Roles of the complement system in human neurode-
generative disorders: pro-inflammatory and tissue
remodeling activities.  Mol Neurobiol 2002, 25:1-17.
6. Benard M, Gonzalez BJ, Schouft MT, Falluel-Morel A, Vaudry D, Chan
P, Vaudry H, Fontaine M: Characterization  of C3a and C5a
receptors in rat cerebellar granule neurons during matura-
tion. Neuroprotective effect of C5a against apoptotic cell
death.  J Biol Chem 2004, 279:43487-43496.
7. Kimura Y, Madhavan M, Call MK, Santiago W, Tsonis PA, Lambris JD,
Del Rio-Tsonis K: Expression of complement 3 and comple-
ment 5 in newt limb and lens regeneration.  J Immunol 2003,
170:2331-2339.
8. Farkas I, Takahashi M, Fukuda A, Yamamoto N, Akatsu H, Baranyi L,
Tateyama H, Yamamoto T, Okada N, Okada H: Complement C5a
receptor-mediated signaling may be involved in neurode-
generation in Alzheimer's disease.  J Immunol 2003,
170:5764-5771.
9. van Beek J, Nicole O, Ali C, Ischenko A, MacKenzie ET, Buisson A,
Fontaine M: Complement anaphylatoxin C3a is selectively
protective against NMDA-induced neuronal cell death.  Neu-
roreport 2001, 12:289-293.
10. Wang Q, Yu S, Simonyi A, Sun GY, Sun AY: Kainic acid-mediated
excitotoxicity as a model for neurodegeneration.  Mol Neuro-
biol 2005, 31:3-16.
11. Pasinetti GM, Tocco G, Sakhi S, Musleh WD, DeSimoni MG, Mas-
carucci P, Schreiber S, Baudry M, Finch CE: Hereditary deficien-
cies in complement C5 are associated with intensified
neurodegenerative responses that implicate new roles for
the C-system in neuronal and astrocytic functions.  Neurobiol
Dis 1996, 3:197-204.
12. Tocco G, Musleh W, Sakhi S, Schreiber SS, Baudry M, Pasinetti GM:
Complement and glutamate neurotoxicity. Genotypic influ-
ences of C5 in a mouse model of hippocampal neurodegen-
eration.  Mol Chem Neuropathol 1997, 31:289-300.
13. Osaka H, McGinty A, Hoepken UE, Lu B, Gerard C, Pasinetti GM:
Expression of C5a receptor in mouse brain: role in signal
transduction and neurodegeneration.  Neuroscience 1999,
88:1073-1082.
14. Mukherjee P, Pasinetti GM: Complement anaphylatoxin C5a
neuroprotects through mitogen-activated protein kinase-
dependent inhibition of caspase 3.  J Neurochem 2001, 77:43-49.
15. Osaka H, Mukherjee P, Aisen PS, Pasinetti GM: Complement-
derived anaphylatoxin C5a protects against glutamate-
mediated neurotoxicity.  J Cell Biochem 1999, 73:303-311.
16. Friedman LK: Selective reduction of GluR2 protein in adult
hippocampal CA3 neurons following status epilepticus but
prior to cell loss.  Hippocampus 1998, 8:511-525.
17. Chan SL, Griffin WS, Mattson MP: Evidence for caspase-medi-
ated cleavage of AMPA receptor subunits in neuronal apop-
tosis and Alzheimer's disease.  J Neurosci Res 1999, 57:315-323.
18. Konteatis ZD, Siciliano SJ, Van Riper G, Molineaux CJ, Pandya S,
Fischer P, Rosen H, Mumford RA, Springer MS: Development of
C5a receptor antagonists. Differential loss of functional
responses.  J Immunol 1994, 153:4200-4205.
19. Vissavajjhala P, Janssen WG, Hu Y, Gazzaley AH, Moran T, Hof PR,
Morrison JH: Synaptic distribution of the AMPA-GluR2 subu-
nit and its colocalization with calcium-binding proteins in rat
cerebral cortex: an immunohistochemical study using a
GluR2-specific monoclonal antibody.  Exp Neurol 1996,
142:296-312.
20. Barnum SR: Complement in central nervous system inflam-
mation.  Immunol Res 2002, 26:7-13.
21. Reiman R, Torres AC, Martin BK, Ting JP, Campbell IL, Barnum SR:
Expression of C5a in the brain does not exacerbate experi-
mental autoimmune encephalomyelitis.  Neurosci Lett 2005,
390:134-138.
22. Drouin SM, Sinha M, Sfyroera G, Lambris JD, Wetsel RA: A protec-
tive role for the fifth complement component (c5) in allergic
airway disease.  Am J 2006, 173:852-857.
23. Leist M, Nicotera P: Apoptosis, excitotoxicity, and neuropa-
thology.  Exp Cell Res 1998, 239:183-201.
24. Choi DW, Koh JY, Peters S: Pharmacology of glutamate neuro-
toxicity in cortical cell culture: attenuation by NMDA antag-
onists.  J Neurosci 1988, 8:185-196.
25. Larm JA, Cheung NS, Beart PM: Apoptosis induced via AMPA-
selective glutamate receptors in cultured murine cortical
neurons.  J Neurochem 1997, 69:617-622.
26. Cheung NS, Carroll FY, Larm JA, Beart PM, Giardina SF: Kainate-
induced apoptosis correlates with c-Jun activation in cul-
tured cerebellar granule cells.  J Neurosci 1998, 52:69-82.
27. Kawasaki H, Morooka T, Shimohama S, Kimura J, Hirano T, Gotoh Y,
Nishida E: Activation and involvement of p38 mitogen-acti-
vated protein kinase in glutamate-induced apoptosis in rat
cerebellar granule cells.  J Biol Chem 1997, 272:18518-18521.
28. Liu HN, Larocca JN, Almazan G: Molecular pathways mediating
activation by kainate of mitogen-activated protein kinase in
oligodendrocyte progenitors.  Brain Res Mol Brain Res 1999,
66:50-61.
29. Fuller G, Veitch K, Ho LK, Cruise L, Morris BJ: Activation of p44/
p42 MAP kinase in striatal neurons via kainate receptors and
PI3 kinase.  Brain Res Mol Brain Res 2001, 89:126-132.
30. Lee A, Whyte MK, Haslett C: Inhibition of apoptosis and prolon-
gation of neutrophil functional longevity by inflammatory
mediators.  J Leukocyte Biol 1993, 54:283-288.
31. Hopkins JI, Jones J, Morgan BP: Non-lethal effects of perforin on
polymorphonuclear leukocytes.  Biochem Soc Trans 1998, 26:S50.
32. Friedman LK, Veliskova J, Kaur J, Magrys BW, Liu H: GluR2(B)
knockdown accelerates CA3 injury after kainate seizures.  J
Neuropathol Exp Neurol 2003, 62:733-750.
33. Jia YH, Zhu X, Li SY, Ni JH, Jia HT: Kainate exposure suppresses
activation of GluR2 subunit promoter in primary cultured
cerebral cortical neurons through induction of RE1-silencing
transcription factor.  Neurosci Lett 2006, 403:103-108.
34. Gorter JA, Petrozzino JJ, Aronica EM, Rosenbaum DM, Opitz T, Ben-
nett MV, Connor JA, Zukin RS: Global ischemia induces down-
regulation of Glur2 mRNA and increases AMPA receptor-
mediated Ca2+ influx in hippocampal CA1 neurons of gerbil.
J Neurosci 1997, 17:6179-6188.
35. Grooms SY, Opitz T, Bennett MV, Zukin RS: Status epilepticus
decreases glutamate receptor 2 mRNA and protein expres-
sion in hippocampal pyramidal cells before neuronal death.
Proc Natl Acad Sci USA 2000, 97:3631-3636.